More Hope, And More Demands, For Pancreatic Cancer Pipeline
Executive Summary
ASCO reflected diverse lay of the land for the challenging development space, with new drugs coming from Merrimack, Halozyme, Threshold and a range of immunotherapy combinations. Meanwhile, Celgene’s Abraxane appears to be on blockbuster track.
You may also be interested in...
Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20
While not perfect, the latest Phase II data for the stromal depleting agent PEGPH20 give cause for optimism for hyaluronan as a biomarker in pancreatic cancer and for Halozyme's Phase III strategy.
Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study
Patient advocacy group is spearheading the genomics-driven trial, which will assess if stratification may finally be possible in pancreatic cancer.
Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests
American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.